Fig. 3From: Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing–remitting multiple sclerosis converting to glatiramer acetateChange in quality of life score by geographic region. aP = .0012 for Latin America vs. Canada/Western Europe at final follow-up. bP = .0008 for change from baseline. FAMS Functional Assessment of Multiple SclerosisBack to article page